Health Promotion Tools for Colorectal Cancer Survivors
(TTBF Trial)
Trial Summary
What is the purpose of this trial?
This clinical trial studies the effect of four different intervention components "tools" on body weight, nutrition, and physical activity in cancer survivors. Studies indicate that people with a history of cancer whose nutrition and physical activity habits are consistent with the American Cancer Society's Nutrition and Physical Activity Guidelines may have longer disease-free survival. The four different intervention components may help patients with a history of cancer adopt recommended health behaviors after they have completed treatment.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, hormonal treatments for breast and prostate cancer are allowed, and co-enrollment in some trials involving medication is permitted.
What data supports the effectiveness of the treatment Tools To Be Fit, Nutrition and Physical Activity Intervention for Cancer Survivors?
Is the Health Promotion Tools treatment safe for colorectal cancer survivors?
How is the 'Tools To Be Fit' treatment different from other treatments for colorectal cancer survivors?
The 'Tools To Be Fit' treatment is unique because it focuses on increasing physical activity and improving nutrition specifically for colorectal cancer survivors, which can help reduce the risk of cancer recurrence and improve overall health. Unlike traditional treatments that may focus on medication or surgery, this approach emphasizes lifestyle changes to enhance quality of life and health outcomes.1691011
Research Team
Erin Van Blarigan, ScD
Principal Investigator
University of California, San Francisco
Eligibility Criteria
This trial is for colorectal cancer survivors, aged 18 or older, who have completed treatment and are ready to improve their nutrition and physical activity. They must own a smartphone, speak English or Spanish, and have a supportive person willing to help. Exclusions include those with exercise contraindications without physician clearance, recent app-based diet/activity tracking, planned major surgeries during the study period, other active cancers (with exceptions), current participation in similar trials, pregnancy intentions during the study period.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Intervention
Participants receive various combinations of text messaging, digital health tool kit, health coaching, and support person training to improve nutrition and physical activity
Follow-up
Participants are monitored for changes in ACS guideline scores, nutrition, physical activity, and other health markers
Treatment Details
Interventions
- Tools To Be Fit (Behavioural Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of California, San Francisco
Lead Sponsor
Suresh Gunasekaran
University of California, San Francisco
Chief Executive Officer since 2022
MBA from Southern Methodist University
Dr. Lukejohn Day
University of California, San Francisco
Chief Medical Officer
MD from Stanford University School of Medicine
Cedars-Sinai Medical Center
Collaborator
David E. Cohen
Cedars-Sinai Medical Center
Chief Medical Officer
MD and PhD in Physiology and Biophysics from Harvard University
Peter L. Slavin
Cedars-Sinai Medical Center
Chief Executive Officer
MD from Harvard Medical School, MBA from Harvard Business School
Dana-Farber Cancer Institute
Collaborator
Dr. Benjamin L. Ebert
Dana-Farber Cancer Institute
Chief Executive Officer
MD from Harvard Medical School, PhD from Oxford University
Dr. Craig A. Bunnell
Dana-Farber Cancer Institute
Chief Medical Officer since 2012
MD from Harvard Medical School, MPH from Harvard School of Public Health, MBA from MIT Sloan School of Management
Robert H. Lurie Cancer Center
Collaborator
University of California, Davis
Collaborator
Rakesh Dixit
University of California, Davis
Chief Executive Officer since 2024
PhD in Biochemistry and Molecular Biology from the University of California, Davis
Suresh Mahabhashyam
University of California, Davis
Chief Medical Officer since 2020
MD from Bangalore Medical College
National Cancer Institute (NCI)
Collaborator
Dr. Douglas R. Lowy
National Cancer Institute (NCI)
Chief Executive Officer since 2023
MD from New York University School of Medicine
Dr. Monica Bertagnolli
National Cancer Institute (NCI)
Chief Medical Officer since 2022
MD from Harvard Medical School